Carboplatin in combination therapy for ovarian cancer

W. W. ten Bokkel Huinink, M. E L van der Burg, A. T. van Oosterom, J. P. Neijt, M. George, J. P. Guastalla, C. H N Veenhof, N. Rotmensz, O. Dalesio, J. B. Vermorken

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalCancer Treatment Reviews
Volume15
Issue numberSUPPL. B
DOIs
Publication statusPublished - 1988

Fingerprint

Carboplatin
Ovarian Neoplasms
Cisplatin
Altretamine
Feasibility Studies
Therapeutics
Combination Drug Therapy
Doxorubicin
Cyclophosphamide

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

ten Bokkel Huinink, W. W., van der Burg, M. E. L., van Oosterom, A. T., Neijt, J. P., George, M., Guastalla, J. P., ... Vermorken, J. B. (1988). Carboplatin in combination therapy for ovarian cancer. Cancer Treatment Reviews, 15(SUPPL. B), 9-15. https://doi.org/10.1016/0305-7372(88)90030-8

Carboplatin in combination therapy for ovarian cancer. / ten Bokkel Huinink, W. W.; van der Burg, M. E L; van Oosterom, A. T.; Neijt, J. P.; George, M.; Guastalla, J. P.; Veenhof, C. H N; Rotmensz, N.; Dalesio, O.; Vermorken, J. B.

In: Cancer Treatment Reviews, Vol. 15, No. SUPPL. B, 1988, p. 9-15.

Research output: Contribution to journalArticle

ten Bokkel Huinink, WW, van der Burg, MEL, van Oosterom, AT, Neijt, JP, George, M, Guastalla, JP, Veenhof, CHN, Rotmensz, N, Dalesio, O & Vermorken, JB 1988, 'Carboplatin in combination therapy for ovarian cancer', Cancer Treatment Reviews, vol. 15, no. SUPPL. B, pp. 9-15. https://doi.org/10.1016/0305-7372(88)90030-8
ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Neijt JP, George M, Guastalla JP et al. Carboplatin in combination therapy for ovarian cancer. Cancer Treatment Reviews. 1988;15(SUPPL. B):9-15. https://doi.org/10.1016/0305-7372(88)90030-8
ten Bokkel Huinink, W. W. ; van der Burg, M. E L ; van Oosterom, A. T. ; Neijt, J. P. ; George, M. ; Guastalla, J. P. ; Veenhof, C. H N ; Rotmensz, N. ; Dalesio, O. ; Vermorken, J. B. / Carboplatin in combination therapy for ovarian cancer. In: Cancer Treatment Reviews. 1988 ; Vol. 15, No. SUPPL. B. pp. 9-15.
@article{ac33dd425d06408bb45474c6eceb00c5,
title = "Carboplatin in combination therapy for ovarian cancer",
abstract = "Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.",
author = "{ten Bokkel Huinink}, {W. W.} and {van der Burg}, {M. E L} and {van Oosterom}, {A. T.} and Neijt, {J. P.} and M. George and Guastalla, {J. P.} and Veenhof, {C. H N} and N. Rotmensz and O. Dalesio and Vermorken, {J. B.}",
year = "1988",
doi = "10.1016/0305-7372(88)90030-8",
language = "English",
volume = "15",
pages = "9--15",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. B",

}

TY - JOUR

T1 - Carboplatin in combination therapy for ovarian cancer

AU - ten Bokkel Huinink, W. W.

AU - van der Burg, M. E L

AU - van Oosterom, A. T.

AU - Neijt, J. P.

AU - George, M.

AU - Guastalla, J. P.

AU - Veenhof, C. H N

AU - Rotmensz, N.

AU - Dalesio, O.

AU - Vermorken, J. B.

PY - 1988

Y1 - 1988

N2 - Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.

AB - Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.

UR - http://www.scopus.com/inward/record.url?scp=0023711367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023711367&partnerID=8YFLogxK

U2 - 10.1016/0305-7372(88)90030-8

DO - 10.1016/0305-7372(88)90030-8

M3 - Article

C2 - 3135934

AN - SCOPUS:0023711367

VL - 15

SP - 9

EP - 15

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. B

ER -